Keyphrases
Glioblastoma
100%
Tumor
56%
Glioma
45%
Recurrent Glioblastoma
42%
Temozolomide
35%
Extent of Resection
26%
Human Mesenchymal Stem Cells (hMSCs)
25%
High-grade Glioma
24%
Astrocytoma
23%
Malignant Glioma
22%
Epigenetics
22%
Reoperation
22%
Hypomethylating Agents
22%
Residual Tumor Volume
18%
Immune Checkpoint Inhibitors
18%
Overall Survival
17%
Targeted Therapy
17%
Surgeons
16%
5-Aminolevulinic Acid (5-ALA)
16%
Decitabine
16%
Clinical Trials
16%
Fluorescence-guided Surgery
15%
Neurosurgeon
15%
Subclonal
15%
Intratumoral Heterogeneity
14%
Chemoradiation
14%
Isocitrate Dehydrogenase 1 (IDH1)
14%
Next-generation Sequencing
14%
Carotid Artery
13%
PD-1 Blockade
13%
CDKN2A mutation
13%
Astrocytes
12%
Karnofsky Performance Status
12%
Tumor Protein p53 (TP53)
12%
Human Glioma
12%
Stem Cell Properties
12%
Survival Benefit
12%
Newly Diagnosed Glioblastoma
12%
Xenograft
11%
Tumor Cells
11%
ARID1A mutation
11%
Anti-PD-1
11%
Transcriptional States
11%
Cerebral Phaeohyphomycosis
11%
Invasive Growth
11%
Immune Heterogeneity
11%
Phase I Trial
11%
DNA Adenine Methylation
11%
Tropism
11%
Cerebellar Glioblastoma
11%
Medicine and Dentistry
Glioblastoma
99%
Neoplasm
86%
Ganglioglioma
71%
Surgery
38%
Oligoastrocytoma
24%
Mesenchymal Stem Cell
22%
Reoperation
22%
Overall Survival
21%
Xenograft
17%
Stem Cell
15%
Carotid Artery
14%
Isocitrate Dehydrogenase
13%
Craniotomy
13%
Aminolevulinic Acid
13%
Surgeon
13%
Targeted Therapy
12%
Epidermal Growth Factor Receptor
12%
Immunity
12%
Programmed Death-Ligand 1
11%
Phase I Trials
11%
Cerebral Phaeohyphomycosis
11%
Lactic Acid
11%
Medulloblastoma
11%
Vasculotropin A
11%
Vestibular Schwannoma
11%
Oncolytic Adenovirus
11%
Germinal Matrix
11%
Hyperlactatemia
11%
Cochlear Nerve
11%
Hodgkin's Lymphoma
11%
Carotid-Cavernous Fistula
11%
Cervical Spine
11%
Vertebral Artery Dissection
11%
Bone Marrow Derived Mesenchymal Stem Cell
11%
Platelet Derived Growth Factor BB
11%
Filum Terminale
11%
BRCA1
11%
Plexin
11%
Verteporfin
11%
Geriatrics
11%
Malignant Neoplasm
11%
Epigenomics
11%
Cell-Free DNA
11%
Liquid Biopsy
11%
Chemotherapy
10%
Next Generation Sequencing
9%
Avelumab
9%
Bevacizumab
9%
Immunocompetent Cell
9%
Karnofsky Performance Status
8%